Ebastine
- Generic Name
- Ebastine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H39NO2
- CAS Number
- 90729-43-4
- Unique Ingredient Identifier
- TQD7Q784P1
- Background
Ebastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.
- Indication
用于伴有或不伴有过敏性结膜炎的过敏性鼻炎（季节性和常年性）。慢性特发性荨麻疹的对症治疗。
- Associated Conditions
- Allergic Rhinitis (AR)
- Associated Therapies
- -
Ebastine Versus Mebeverine in IBS Patients
Phase 3
Recruiting
- Conditions
- IBS - Irritable Bowel SyndromeIBS
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Guy Boeckxstaens
- Target Recruit Count
- 200
- Registration Number
- NCT05815602
- Locations
- 🇧🇪
UZLeuven, Leuven, Vlaams-Brabant, Belgium
🇧🇪GZA, Antwerpen, Belgium
🇧🇪AZ St-Maarten, Mechelen, Antwerpen, Belgium
Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria
Phase 4
Completed
- Conditions
- Urticaria
- Interventions
- First Posted Date
- 2013-09-12
- Last Posted Date
- 2014-02-19
- Lead Sponsor
- Grupo de Alergología Clínica y Experimental
- Target Recruit Count
- 150
- Registration Number
- NCT01940393
- Locations
- 🇨🇴
Medellin, Medellin, Antioquia, Colombia
Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- KU Leuven
- Target Recruit Count
- 200
- Registration Number
- NCT01908465
- Locations
- 🇧🇪
ZOL (Ziekenhuis Oost-Limburg), Genk, Limburg, Belgium
🇳🇱Academisch Medisch Centrum, Amsterdam, Noord-Holland, Netherlands
🇳🇱Rijnstate, Arnhem, Gelderland, Netherlands
Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists
- First Posted Date
- 2010-06-16
- Last Posted Date
- 2016-01-28
- Lead Sponsor
- KU Leuven
- Target Recruit Count
- 55
- Registration Number
- NCT01144832
- Locations
- 🇧🇪
University hospitals Leuven, Leuven, Vlaams-Brabant, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath